Head-To-Head Survey: Jasper Therapeutics (NASDAQ:JSPR) & CytRx (OTCMKTS:CYTR) – Defense World

Jasper Therapeutics (NASDAQ:JSPR Get Rating) and CytRx (OTCMKTS:CYTR Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, earnings, risk, analyst recommendations and profitability.

Earnings & Valuation

This table compares Jasper Therapeutics and CytRxs top-line revenue, earnings per share and valuation.

Institutional & Insider Ownership

63.0% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of CytRx shares are owned by institutional investors. 12.8% of CytRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Jasper Therapeutics and CytRxs net margins, return on equity and return on assets.

Volatility & Risk

Jasper Therapeutics has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, CytRx has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Jasper Therapeutics and CytRx, as reported by MarketBeat.

Jasper Therapeutics currently has a consensus price target of $15.00, suggesting a potential upside of 415.46%. Given Jasper Therapeutics higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than CytRx.

About Jasper Therapeutics (Get Rating)

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

About CytRx (Get Rating)

CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed cytotoxin agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides ACDx, an albumin companion diagnostic product to identify patients with cancer who are most likely to benefit from treatment with these drug candidates. CytRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Read this article:
Head-To-Head Survey: Jasper Therapeutics (NASDAQ:JSPR) & CytRx (OTCMKTS:CYTR) - Defense World